|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Rini, Brian I.; Powles, Thomas; Atkins, Michael B.; Escudier, Bernard; McDermott, David F.; Suarez, Cristina; Bracarda, Sergio; Stadler, Walter M.; Donskov, Frede; Lee, Jae Lyun; Hawkins, Robert; Ravaud, Alain; Alekseev, Boris; Staehler, Michael; Uemura, Motohide; De Giorgi, Ugo; Mellado, Begona; Porta, Camillo; Melichar, Bohuslav; Gurney, Howard; Bedke, Jens; Choueiri, Toni K.; Parnis, Francis; Khaznadar, Tarik; Thobhani, Alpa; Li, Shi; Piault-Louis, Elisabeth; Frantz, Gretchen; Huseni, Mahrukh; Schiff, Christina; Green, Marjorie C. und Motzer, Robert J.
(2019):
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
In: Lancet, Bd. 393, Nr. 10189: S. 2404-2415
Powles, Thomas; Lackner, Mark R.; Oudard, Stéphane; Escudier, Bernard; Ralph, Christy; Brown, Janet E.; Hawkins, Robert E.; Castellano, Daniel; Rini, Brian I.; Staehler, Michael D.; Ravaud, Alain; Lin, Wei; O'Keeffe, Bridget; Wang, Yulei; Lu, Shan; Spoerke, Jill M.; Huw, Ling-Yuh; Byrtek, Michelle; Zhu, Rui; Ware, Joseph A. und Motzer, Robert J.
(2016):
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
In: Journal of Clinical Oncology, Bd. 34, Nr. 14:
1660-U204